PGR and neoplasm: Before matching, the number of ER+ subjects was 992 (67.6% of the cohort), and they exhibited significant differences in age, lymph node status, tumor size, uses of chemotherapy, radiation therapy, expressions of PR and HER2 compared to ER− subjects (Table 1).